Alunbrig can be used as a second-line treatment for patients with anaplastic lymphoma kinase-postive metastastic non-small cell lung cancer who are already taking Pfizer’s drug crizotinib — the standard treatment for the disease.
Takeda gained rights to Alunbrig through its $5.2 billion acquisition of Ariad Pharmaceuticals in February.
More articles on supply chain:
FDA approves new osteoporosis drug
Supply chain tip of the week: Target services — not supplies — for cost savings
FDA approves RFID device to locate breast lumps
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
